EGFR and non-small cell lung carcinoma: Approximately 85% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC)3, and more than 80% of NSCLC cases are diagnosed at an advanced stage with activating epidermal growth factor receptor (EGFR) mutations4.